Zurlo J J, O'Neill D, Polis M A, Manischewitz J, Yarchoan R, Baseler M, Lane H C, Masur H
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Ann Intern Med. 1993 Jan 1;118(1):12-7. doi: 10.7326/0003-4819-118-1-199301010-00003.
To determine the clinical significance of cytomegalovirus (CMV) blood and urine cultures in patients with human immunodeficiency virus (HIV) infection.
Inception cohort of patients with HIV infection and CMV culture data.
Government referral-based research hospital.
A total of 322 HIV-infected patients who had a CMV blood culture and 293 HIV-infected patients who had a CMV urine culture within 7 days of a CD4 determination.
Cytomegalovirus blood and urine culture results; circulating CD4 lymphocyte counts; pathologic or retinopathic findings of CMV disease.
Nine of 26 patients (34.6%) with CMV viremia subsequently developed CMV end-organ disease compared with 11 of 74 (14.9%) patients without viremia, (difference, 19.7%; 95% CI, -0.3% to 39.7%). Fifteen of 47 patients (31.9%) with CMV viruria developed end-organ disease compared with 4 of 43 (9.3%) patients without viruria, (difference, 22.6%; CI, 6.7% to 38.5%). Cytomegalovirus culture positivity had poor predictive value for the subsequent development of end-organ disease (35% for viremia and 28% for viruria). Further, patients with proven end-organ disease were often not viremic (45%), but most were viruric (88%). Cytomegalovirus viremia did not correlate with the presence of either fever or weight loss in this patient group. Both blood culture positivity and urine culture positivity varied inversely with the CD4 count (P = 0.0001 for both associations).
The likelihood that a blood or urine culture will be positive in a patient with HIV infection correlates better with immunologic status than with current or future clinical status. Although the absence of CMV viruria may suggest that CMV disease is not present, CMV blood and urine cultures have poor diagnostic and predictive value and therefore should be used primarily for research purposes or drug susceptibility testing and not for making clinical decisions.
确定巨细胞病毒(CMV)血液和尿液培养在人类免疫缺陷病毒(HIV)感染患者中的临床意义。
对有HIV感染和CMV培养数据的患者进行起始队列研究。
基于政府转诊的研究医院。
共有322例HIV感染患者进行了CMV血液培养,293例HIV感染患者在CD4测定的7天内进行了CMV尿液培养。
巨细胞病毒血液和尿液培养结果;循环CD4淋巴细胞计数;CMV疾病的病理或视网膜病变表现。
26例CMV病毒血症患者中有9例(34.6%)随后发生了CMV终末器官疾病,而74例无病毒血症患者中有11例(14.9%)发生了终末器官疾病(差异为19.7%;95%可信区间,-0.3%至39.7%)。47例CMV病毒尿患者中有15例(31.9%)发生了终末器官疾病,而43例无病毒尿患者中有4例(9.3%)发生了终末器官疾病(差异为22.6%;可信区间,6.7%至38.5%)。CMV培养阳性对随后发生终末器官疾病的预测价值较差(病毒血症为35%,病毒尿为28%)。此外,确诊为终末器官疾病的患者通常没有病毒血症(45%),但大多数有病毒尿(88%)。在该患者组中,CMV病毒血症与发热或体重减轻均无相关性。血液培养阳性和尿液培养阳性均与CD4计数呈负相关(两种关联的P值均为0.0001)。
HIV感染患者血液或尿液培养呈阳性的可能性与免疫状态的相关性优于与当前或未来临床状态的相关性。虽然没有CMV病毒尿可能提示不存在CMV疾病,但CMV血液和尿液培养的诊断和预测价值较差,因此主要应用于研究目的或药物敏感性检测,而不应用于临床决策。